Slide 1: Business update – Emerging stronger
Business update Emerging stronger Evotec SE, Hamburg, 28 July 2023
Slide 2: 2023 – so far, a coin with two sides: exciting progress…
2023 – so far, a coin with two sides: exciting progress… Most relevant transactions 2022/2023 Broadened and deepened strategic alliance in neurodegeneration Exclusive strategic partnership for development • Extension and expansion for eight more years of iPSC-based beta-cell replacement therapy in d
Slide 3: …while bouncing back better from a criminal act against us
…while bouncing back better from a criminal act against us Development since detection of cyber-attack and plans forward Productivity ~10% ~50% ~80% ~90% >100% Shut-down / Containing risk of propagation Forensics protecting data assets Zero Restart compromise All drug discovery systems at 100% Robus
Slide 4: Strong start in Q1 – massive Q2 impact of temporary nature
Strong start in Q1 – massive Q2 impact of temporary nature H1 2023 revenue1 composition by quarters/months (€m) Business dynamics intact € ~70 m (net) • Very strong start to the year with > 30% revenue growth in Q1 2023 • Just – Evotec Biologics ahead of plan & mid-term plans based on closing of Tec
Slide 5: Approx. 8% revenue one-off impact due to cyber-attack
Approx. 8% revenue one-off impact due to cyber-attack Revenue guidance bridge € 820 – 840 m € 750 – 790 m Manageable one-off effects and € -100 m adjusting to market sentiment € 20 – 40 m € -20 m € 30 m • Revenues (net), missed in Q2 2023, representing ~8% of initial revenue guidance • Missed revenu
Slide 6: Embracing the moment to learn, grow, and become even more efficient
Embracing the moment to learn, grow, and become even more efficient Better, safer, agile Bouncing back better • Immediate cost savings 1 Value Protection Programme (VPP) • Leaner processes in SG&A • Focused capacity build-up in more demanding markets • Portfolio realignment 2 Optimised capital alloc
Slide 7: Offsetting one-off burdens
Offsetting one-off burdens Adj. EBITDA guidance bridge € 115 – 130 m Better, safer & more efficient € -25 m • Net one-off costs of € 25 m to re- build business • Missed revenues come with € -55 – € -10 m € 60 – 80 m moderate saving of variable costs € ~25 m -60 m (e.g. materials, …) € ~15 m • Bigges
Slide 8: New guidance reflecting cyber-attack
New guidance reflecting cyber-attack Guidance 2023 Guidance 2023, new Guidance 2023, old FY 20221 Group revenues € 750 – 790 m € 820 – 840 m € 751 m (at constant fx-rates2) (€ 765 – 805 m) (€ 835 – 855 m) Unpartnered R&D3 € 60 – 70 m € 70 – 80 m € 70 m Adjusted EBITDA € 60 – 80 m € 115 – 130 m € 101
Slide 9: Our mid-term aspirations are unchanged
Our mid-term aspirations are unchanged 2020-2025 estimated key performance indicator goals1 Group revenues Adjusted group EBITDA in € m in € m >100% ≥180% 500.9 >1,000 106.6 ≥300 Unpartnered R&D Co-owned projects2 in € m >100% >100% 46.4 >100 118 >250 PAGE 9 1 As presented H1/2021 2 Incl. equity par
Slide 10: How to get there …
How to get there … Mid-term adj. EBITDA bridge 2022 2025 aspiration Well-balanced cascade € ~300 m • Average annual growth of Base Business adj. EBITDA of 15% due to € ~60 m − Robust top-line growth € ~170 m − Operating leverage € ~70 m − Efficiency (Value Protection € 113 m € 25 m Programme) € 101
Slide 11: Executing to accelerate growth along Action Plan 2025
Executing to accelerate growth along Action Plan 2025 Selected major newsflow 2023 PanOmics • New strategic partnerships and expansions of co-owned alliances • New clinical trial initiations, e.g. Bayer • Significant progress of later stage co-owned pipeline iPSCs • New strategic partnerships, e.g.
Slide 12: pRescaRcHnevensTors
pRescaRcHnevensTors
Slide 13: Volker Braun, SVP Head of Global Investor Relations & ESG
Volker Braun SVP Head of Global Investor Relations & ESG +49 (0) 40 560 81-775 +49 (0) 151 1940 5058 (m) volker.braun@evotec.com